Llombart Cussac, AntonioPérez García, José ManuelBellet Ezquerra, MeritxellDalenc, FlorenceGil Gil, MiguelRuiz Borrego, ManuelGavilá, JoaquínSchmid, PeterZamora, PilarWheatley, DuncanMartínez de Dueñas, EduardoAmillano, KepaDi Cosimo, SerenaAntón, AntonioCottu, Paul-HenriShimizu, EileenFernandez Pinto, MelissaSampayo Cordero, MiguelCortés, Javier2025-07-212025-07-212025-06-172059-7029https://hdl.handle.net/2445/222387Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the mainstay for hormone receptor (HR)positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). While the approved CDK4/6i have demonstrated significant improvements in progression-free survival (PFS), inconsistencies exist for overall survival (OS) benefits. Here, we report updated efficacy results from PARSIFAL, a randomized phase II study, that evaluated first-line palbociclib with either letrozole or fulvestrant in postmenopausal patients with endocrine-sensitive, HR-positive/HER2-negative ABC. Patients and methods: PARSIFAL-LONG was an international, multicenter, observational study that extended follow-up for patients included in PARSIFAL. The primary objective evaluated updated OS of palbociclib combined with endocrine therapy (fulvestrant or letrozole). Secondary objectives included updated investigator-assessed PFS and subsequent antineoplastic therapies. Exploratory endpoints included identification of new clinical prognostic markers for OS, specifically PFS duration. Results: A total of 419 of 486 (86.2%) patients from PARSIFAL were included. Median follow-up was 7.3 years (interquartile range 6.7-7.7 years). At data cut-off (8 January 2024), no differences in efficacy were observed between fulvestrant and letrozole for OS (hazard ratio 1.01, 95% confidence interval [CI], 0.80-1.28, P = 0.927) or PFS (hazard ratio 1.06,95% CI, 0.85-1.31, P = 0.612). Median OS for the overall PARSIFAL-LONG population was 61.8 months (95% CI 56.5-68.4 months), representing the highest OS reported to date for palbociclib and aligning with outcomes observed for other CDK4/6i in this setting. Median PFS was 32.6 months (95% CI 27.5-38.1 months). A total of 85 (20.3%) patients were defined as early progressors (PFS < 12 months). These patients had a shorter median post-progression OS than patients who remained progression free at 12 months (18.7 versus 27.4 months; hazard ratio 0.65, P = 0.004). Conclusions: Extended analysis from PARSIFAL confirmed no difference between fulvestrant and letrozole when combined with palbociclib for patients with endocrine-sensitive, HR-positive/HER2-negative ABC. Efficacy results were consistent with those reported in the pivotal first-line trials involving CDK4/6i. Progression within the first year on CDK4/6i may indicate a poorer prognosis.9 p.application/pdfengcc by-nc-nd (c) Llombart Cussac, Antonio et al, 2025http://creativecommons.org/licenses/by-nc-nd/3.0/es/AntihormonesTractament adjuvant del càncerHormone antagonistsAdjuvant treatment of cancerinfo:eu-repo/semantics/article2025-07-18info:eu-repo/semantics/openAccess40532361